Type 2 & other diabetes

Efficacy and hypoglycaemia outcomes of once‐weekly insulin icodec versus once‐daily basal insulin comparators across baseline HbA1c , body mass index (BMI) and duration of type 2 diabetes subgroups: A post hoc analysis of ONWARDS 1–5

Diabetes Obes MetabPublished Post hoc analysis of the ONWARDS 1–5 randomised trials

Authors' conclusion

The efficacy and hypoglycaemia profile of icodec versus OD basal insulin comparators was overall consistent across trial populations irrespective of baseline HbA1c, BMI or T2D duration.

Study context

Population
Adults with T2D, insulin-naive (ONWARDS 1, 3 and 5) and insulin-experienced (ONWARDS 2 and 4); subgroups by baseline HbA1c (≤8%, >8% to ≤9%, >9%), BMI (<25, ≥25 to <30, ≥30 to <35, ≥35 kg/m²) and T2D duration (<5, ≥5 to <10, ≥10 to <15, ≥15 years)5 trials
Comparison
Once-weekly insulin icodec vs once-daily basal insulin comparators
Primary endpoint
Change in HbA1c from baseline
Follow-up
Planned end of treatment
Methodological detailssubgroup analysis, five phase 3a trials, analysed by trial
  • Subgroup analysis
  • Five phase 3a trials
  • Analysed by trial

Primary result

As reported in the abstract

Change in HbA1c and achievement of HbA1c <7% without clinically significant or severe hypoglycaemia, across baseline HbA1c, BMI and T2D duration subgroups
  • Estimated treatment differences for change in HbA1c and ORs for HbA1c <7% without clinically significant or severe hypoglycaemia, icodec vs once-daily (OD) comparators, overall consistent across baseline HbA1c, BMI and T2D duration subgroups
  • No statistically significant treatment by subgroup interactions
  • Post hoc analysis

Safety

Hypoglycaemia rates numerically low for both arms and consistent across subgroups in ONWARDS 1-3 and 5

Original publication

Efficacy and hypoglycaemia outcomes of once‐weekly insulin icodec versus once‐daily basal insulin comparators across baseline HbA1c , BMI and duration of type 2 diabetes subgroups: A post hoc analysis of ONWARDS 1–5. Diabetes Obes Metab. Published 12 December 2025. doi:10.1111/dom.70358

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.